CaliPharms P/E Ratio

CaliPharms (KGET) currently reports a P/E ratio of -0.4. That is below the Industrials sector average of 33.61. Use the charts on this page to explore CaliPharms's P/E ratio history and peer comparisons.

CaliPharms's P/E ratio of -0.4 is lower than the Industrials sector average of 33.61. That is roughly 101.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates CaliPharms's market price to a fundamental measure such as earnings, sales, or book value. At -0.4, KGET can look expensive or cheap only in context — versus its own history, growth rate, and Industrials peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -0.4, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is 33.61. From there, open related valuation or income-statement pages for CaliPharms, and consider following KGET for alerts when major investors trade the stock.

CaliPharms is classified in the Industrials sector. On P/E ratio, it currently shows -0.4 versus a sector average near 33.61. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing KGET with unrelated industries.